Moreover, the ongoing STAPRA trial, StopRA study and APIPPRA trial aim to prevent progression of the disease among patients with high titers of ACPA or ACPA and RF IgM utilizing atorvastatin, hydroxyquinone and abatacept before the onset of RA [159]. Here, CD40LG is linked to rheumatoid arthritis.